Alex Snow
Chief Executive Officer
Alex is an experienced entrepreneur with extensive, executive leadership and a proven track record in AI drug discovery.
He recently stepped down as Chairman of AI drug discovery company Exscientia prior to its successful $2.6 billion Nasdaq IPO. In 2015 he co-founded Oxford Sciences Innovation Plc (OSI), now called Oxford Science Enterprises, and raised more than £600 million to commercialise world-leading science originating at Oxford University. Prior to OSI, Alex spent 20 years in investment banking and fund management, including as CEO of Lansdowne Partners UK LLP, a long-standing shareholder in Sensyne, and as founder and CEO of Evolution Group, a UK mid-market investment banking and wealth management group sold to Investec Bank.